89SrCI2联合“云克”治疗乳腺癌骨转移的临床价值

The clinical value of strontium-89 combined with 99Tc-MDP in treatment of patients with bone metastases of breast cancer

目的：探讨89SrCI2联合锝亚甲基二膦酸盐（云克）治疗乳腺癌多发骨转移的临床价值。方法：对87例乳腺癌骨转移患者分为89SrCI2组（A组）42例，89SrCI2联合“云克”组（B组）45例，治疗后随访患者的骨痛缓解情况、全身骨显像变化情况以及癌胚抗原（CEA）、糖类抗原15—3（CAl5—3）变化情况。结果：B组患者骨痛缓解的总有效率93．3％。骨显像完全缓解（CR）＋部分缓解（PR）率为48．9％，CEA水平下降为（23．55±11．02）ng／ml，CAl5-3水平下降为（56．23±28．29）U／ml，均与A组比较有统计学意义。结论：89SRCl2联合“云克”治疗乳腺癌多发骨转移，骨痛缓解率明显提高，CEA、cAl5-3水平明显下降，而毒副作用未见明显增加。

Objective： To evaluate the clinical value of 89Sr combined with 99Tc-MDP in treatment of multiple bone metastases of breast cancer. Methods： 87 patients with bone metastases of breast cancer were divided into Group A and Group B. 42 patients in Group A were treated with 89Sr only, and the other 45 patients in Group B were treated with 89Sr combined with 99Tc-MDP. Pain palliation ,the changes of bone imaging and carcinoembryonic antigen（CEA） level and carhohrdyate antigen 153（CA153） level for all patients were observed and followed. Resnlts： The total effective rate of pain palliation in Group B was 93.3%, and the rate of complete relief （CR.） and partial relief （PP.） in bone imaging was 48.9% and the decrease of CEA was 23.55 _＋ 11.02ng/m1 and the decrease of CA153 was 56.23 4- 28.29 U/ml, which were different from those in Group A. Conclusion： The combination of Sqsr and 99Tc-MDP in the treatment of patients with bone metastases of breast cancer could increase rate pain remission and decrease CEA and CA153 level and not increase side-effect obviously.